Clinical Trial Update: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating STRO-002 in Chinese adults with epithelial ovarian cancer and other advanced malignant solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Malignant Solid Tumors
• Ovarian Cancer

Drugs mentioned

• STRO-002 (STRO-002)

Snippet

Sponsor: Tasly Pharmaceutical Group Co., Ltd | Conditions: Neoplasm Malignant | Phase 1, Phase 2 | Status: COMPLETED